Tango Therapeutics Inc (NASDAQ: TNGX)’s stock price has dropped by -0.94 in relation to previous closing price of 7.43. Nevertheless, the company has seen a loss of -12.49% in its stock price over the last five trading days. seekingalpha.com reported 2024-09-10 that Tango Therapeutics, Inc. offers high-risk, high-reward exposure to PRMT5-inhibitor drugs, with two candidates, TNG908 and TNG462, targeting MTAP-deleted cancers, a substantial market opportunity. TNGX stock volatility is influenced by competitors’ PRMT5 data, with recent fluctuations driven by Amgen and Mirati’s clinical results. Tango’s financial stability is supported by >$300M in cash, a Gilead partnership, and a funding runway until 2027, covering key clinical readouts.
Is It Worth Investing in Tango Therapeutics Inc (NASDAQ: TNGX) Right Now?
Company’s 36-month beta value is 0.84.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TNGX is 57.71M, and currently, short sellers hold a 18.11% ratio of that floaft. The average trading volume of TNGX on September 27, 2024 was 913.26K shares.
TNGX’s Market Performance
TNGX stock saw a decrease of -12.49% in the past week, with a monthly decline of -35.44% and a quarterly a decrease of -13.82%. The volatility ratio for the week is 6.76%, and the volatility levels for the last 30 days are 9.36% for Tango Therapeutics Inc (TNGX).. The simple moving average for the past 20 days is -23.68% for TNGX’s stock, with a -21.67% simple moving average for the past 200 days.
Analysts’ Opinion of TNGX
Many brokerage firms have already submitted their reports for TNGX stocks, with Jefferies repeating the rating for TNGX by listing it as a “Buy.” The predicted price for TNGX in the upcoming period, according to Jefferies is $19 based on the research report published on July 17, 2024 of the current year 2024.
Piper Sandler gave a rating of “Overweight” to TNGX, setting the target price at $18 in the report published on February 12th of the current year.
TNGX Trading at -24.44% from the 50-Day Moving Average
After a stumble in the market that brought TNGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.51% of loss for the given period.
Volatility was left at 9.36%, however, over the last 30 days, the volatility rate increased by 6.76%, as shares sank -35.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.59% lower at present.
During the last 5 trading sessions, TNGX fell by -12.49%, which changed the moving average for the period of 200-days by -19.83% in comparison to the 20-day moving average, which settled at $9.44. In addition, Tango Therapeutics Inc saw -25.66% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TNGX starting from Third Rock Ventures IV, L.P., who sale 67,400 shares at the price of $10.53 back on Sep 13 ’24. After this action, Third Rock Ventures IV, L.P. now owns 16,859,075 shares of Tango Therapeutics Inc, valued at $709,756 using the latest closing price.
Third Rock Ventures IV, L.P., the Affiliate of Tango Therapeutics Inc, proposed sale 67,400 shares at $10.50 during a trade that took place back on Sep 13 ’24, which means that Third Rock Ventures IV, L.P. is holding shares at $707,700 based on the most recent closing price.
Stock Fundamentals for TNGX
Current profitability levels for the company are sitting at:
- -3.12 for the present operating margin
- 0.94 for the gross margin
The net margin for Tango Therapeutics Inc stands at -2.74. The total capital return value is set at -0.39. Equity return is now at value -50.58, with -30.62 for asset returns.
Based on Tango Therapeutics Inc (TNGX), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -3.17. The debt to equity ratio resting at 0.15. The interest coverage ratio of the stock is -227.96.
Currently, EBITDA for the company is -111.76 million with net debt to EBITDA at 0.11. When we switch over and look at the enterprise to sales, we see a ratio of 18.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.49.
Conclusion
In a nutshell, Tango Therapeutics Inc (TNGX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
